Restart Life Sciences Corp.
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. … Read more
Restart Life Sciences Corp. (NMLSD) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -1.238x
Based on the latest financial reports, Restart Life Sciences Corp. (NMLSD) has a cash flow conversion efficiency ratio of -1.238x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-77.59K) by net assets ($62.67K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Restart Life Sciences Corp. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Restart Life Sciences Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Restart Life Sciences Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Restart Life Sciences Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thunderbird Minerals Corp.
V:BIRD
|
-0.295x |
|
World Chess PLC
LSE:CHSS
|
0.034x |
|
Next10 Inc
PINK:NXTN
|
-0.058x |
|
Liminatus Pharma, Inc. Warrants
NASDAQ:LIMNW
|
0.365x |
|
Biztech Konsulting SA
WAR:BTK
|
N/A |
|
Neovacs S.A.
PA:ALNEV
|
-0.129x |
|
Reem Capital Corp.
V:REEM-P
|
-0.390x |
|
Theracryf Plc
LSE:TCF
|
-0.146x |
Annual Cash Flow Conversion Efficiency for Restart Life Sciences Corp. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Restart Life Sciences Corp. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-299.07K | $-71.77K | 0.240x | -29.91% |
| 2023-12-31 | $-810.60K | $-277.53K | 0.342x | +100.59% |
| 2022-12-31 | $41.34K | $-2.41 Million | -58.281x | -1274.84% |
| 2021-12-31 | $459.10K | $-1.95 Million | -4.239x | -1218.23% |
| 2020-12-31 | $2.66 Million | $-856.53K | -0.322x | -- |